Musculoskeletal ultrasound as a biomarker of remission – results from a one-year prospective study in patients with rheumatoid arthritis

Tanya Sapundzhieva, Rositsa Karalilova, Anastas Batalov

Medical University of Plovdiv, Medical Faculty, Department of Propaedeutic of Internal Diseases, Rheumatology Clinic, University Hospital ‘Kaspela’, Plovdiv, Bulgaria

Abstract

Aims: To assess the role of musculoskeletal ultrasound (MSUS) as a biomarker of remission and to compare the rates of clinical and imaging remission in patients with rheumatoid arthritis (RA) on different types of treatment. Material and methods: One hundred and forty-one patients underwent physical and ultrasound examination at 5 visits (at baseline and after 1, 3, 6, and 12 months). Patients were divided into two groups according to the type of treatment, which involved synthetic (sDMARDs) and biologic (bDMARDs) disease-modifying antirheumatic drugs. Ultrasound assessment of the wrist, second and third metacarpophalangeal, second and third proximal interphalangeal joints, and the second and fifth metatarsophalangeal joints was performed on gray scale ultrasound (GSUS) and on power Doppler ultrasound (PDUS) (German US7-score). The rate of imaging and clinical remission (DAS28, SDAI, CDAI, and Boolean) was established. The percentage of patients in clinical remission with persistent PD signal was assessed. Results: In the sDMARDs group at month twelve, 43.6% of the patients achieved DAS28 remission, 5.1% – SDAI, 3.8% – CDAI, and 3.8% – Boolean remission. In the bDMARDs group 49.2% achieved DAS28 remission, 6.3% – SDAI, 4.8% – CDAI, and 4.8% – Boolean remission. Irrespective of which clinical index was applied, all patients in clinical remission had persistent synovial hypertrophy on GSUS. Synovial PD signal (PDUS score≥1) was detected in 77% and 71% of patients in DAS28 remission in the sDMARDs and bDMARDs group, respectively. Patients in SDAI, CDAI and Boolean remission in both treatment groups did not have a positive PD signal. Conclusions: There is persistence of synovitis both in patients on sDMARDs and bDMARDs in DAS28 clinical remission. This fact points to a discordance between DAS28 clinical remission and the imaging remission assessed by MSUS irrespective of the type of treatment. MSUS may be a feasible imaging method for the assessment of residual inflammation in daily rheumatology practice.

Keywords: ultrasound; remission; rheumatoid arthritis; biomarker

Introduction

Musculoskeletal ultrasound (MSUS) is included in the European League Against Rheumatism (EULAR) recommendations as a valuable imaging tool in patients with rheumatoid arthritis (RA) [1]. In an ideal case, remission is defined as an absence of disease symptoms and development of structural progression and functional deficit over time [2]. However, evidence exists that some patients with RA experience radiographic progression despite being in clinical remission [3]. This may be explained by the persistence of subclinical joint inflammation which can only be detected through sensitive imaging techniques such as MSUS and magnetic resonance imaging [4-6]. MSUS has been proved to be more sensitive than physical examination for the detection of synovitis [7]. Evidence exists that the presence of a power Doppler (PD) signal in RA patients in clinical remission predicts structural progression and a recent relapse [4,8-10].

Studies have shown that clinical remission established on the basis of different indices (Disease Activity Score for 28 joints (DAS28), DAS 28 ≤2.6 [11]; Sim-
Musculoskeletal ultrasound as a biomarker of remission

plified Disease Activity Index (SDAI), SDAI ≤3.3 [12]; Clinical Disease Activity Index (CDAI), CDAI ≤2.8 [13]; ACR/EULAR definition of remission, 2011 [2]) does not entirely correspond to imaging remission. In order to improve disease outcomes US examination of the joints in patients in clinical remission may be used to guide therapeutic decisions, for example drug tapering [14-17].

Prior to use MSUS for the assessment of remission, the following questions should be addressed: 1) How many and which joints should be examined?; 2) Which scan, dorsal and/or volar, of hand joints should be used?; 3) What should be the position of the joints during the exam?; and 4) Which definition and grading scales for synovitis should be used? [18]. There is evidence that shows that the results of scoring a reduced number of joints correlate to a great extent with those involving the assessment of 78 joints [19]. There are accepted US definitions of synovial hypertrophy, effusion and tenosynovitis [20]. Regarding the most appropriate scan, there is evidence that synovitis is more frequently detected through a palmar scan of metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints in their proximal part than through a dorsal scan [21,22]. Different US scores exist for the assessment of disease activity and of treatment response. The German US7-score has been demonstrated to reflect disease activity and to be suitable for monitoring therapy in daily rheumatology practice [23,24].

There are different definitions of US remission. Some authors define it as an absence of joints with PD signal [9,25-27]. Others accept a more stringent definition, which requires the absence of synovitis both on a gray scale (GS) and PDUS [28]. Van der Ven et al (2017) accept a minimal amount of synovitis on GS and define US remission as a gray scale grade of synovitis ≤1 and power Doppler grade of synovitis =0 for each scanned joint [29]. Some authors accept a minimal residual PD signal (total PD activity score ≤1) [30].

The primary aim of our study was to assess the role of US examination (US7 score) as a biomarker for remission and to compare the rates of clinical and imaging remission in a cohort of patients with RA on different types of treatment followed for a period of one year. Secondary goals were to find which definition of clinical remission best correlates with the presence of US remission, i.e. which is the clinical definition characterized by the lowest rate of PD positive synovitis in both treatment groups.

Material and methods

Patients

One hundred and forty-one patients with RA were consecutively enrolled in this prospective study between April 2016 and January 2018. Inclusion criteria were: diagnosis of RA according to ACR/EULAR 2010 classification criteria [31] and moderate or high disease activity according to DAS28(CRP). Patients were divided into two groups as standard of care according to the treating rheumatologist: Group 1 included patients treated with synthetic disease-modifying antirheumatic drugs (sDMARDs) and Group 2 was comprised of patients on biologic DMARDs (bDMARDs). After enrollment in the study, therapy was either initiated (in patients with newly diagnosed RA) or escalated according to the treat-to-target strategy. The rate of clinical and imaging remission was recorded. All patients underwent physical and ultrasound examination at 5 visits – at baseline (Visit 0–V0) and after 1 (V1), 3 (V2), 6 (V3) and 12 (V4) months. The study was approved by the Ethical Committee of the Medical University of Plovdiv. Informed consent was obtained from all subjects.

Clinical assessment

Twenty-eight joints were evaluated by the same assessor for swelling and/or tenderness: bilaterally PIP and MCP joints, wrist, elbow, shoulder and knee joints. Pain intensity was measured on a visual-analogue scale (VAS) from 0-10 cm. The assessor was blinded to the patients’ previous treatment group/type. For assessment the disease activity three indices were calculated – DAS28, SDAI and CDAI.

Laboratory parameters

C-reactive protein (CRP) level (normal value ≤6.0 mg/l) was obtained at baseline, V2 and V4. IgM-Rheumatoid factor (IgM-RF: normal value <20 U/l) and anti-citrullinated protein antibodies (ACPA: normal value <20 U/l) were assessed at baseline.

Ultrasound assessment

US assessment was conducted by an assessor who was blinded to the patients’ clinical data and type of treatment. MSUS of wrist, hands and forefoot was performed using MyLab 7, Esaote, Italy machine equipped with a multi-frequency linear probe (10-18 MHz). GSUS frequency was 12-18 MHz depending on the examined joint and GSUS gain was estimated based on joint regions and patients, yielding an average of 50%. Settings for PDUS were as follows: frequency 9.1 MHz; pulse repetition frequency 500–750 Hz; PDUS gain in relation to joint regions and patients, amounting to 50% average; low wall filter We examined by GSUS and PDUS 7 joints of the clinically dominant hand/foot, affected more by swelling or tenderness, by using the German US7-score (wrist, second and third MCP and PIP, second and fifth metatarsophalangeal (MTP) joints [23,24]. Several parameters were assessed according to the Outcome Measures in Rheumatology (OMERACT) definitions of pathology, including presence of synovitis, tenosynovitis/paratenon-
itis and erosions [20]. The wrist joint was assessed for synovitis and tenosynovitis on dorsal, palmar and ulnar scan. Palmar scan was used to assess MCP2 and MCP3 for synovitis and tenosynovitis; and dorsal scan for paratenonitis. Erosions were assessed on the dorsal, palmar and for MCP2 also on the radial scan. PIP2 and PIP3 were assessed for synovitis on the palmar scan and for erosions on the dorsal and palmar scan. MTP2 and MTP5 were assessed for synovitis on the dorsal scan and for erosions on the dorsal and plantar scan (for MTP2) and on the dorsal, plantar and lateral scan (for MTP5). Synovitis on GSUS was scored on a semi-quantitative scale (0 to 3) [21]. Tenosynovitis/paratenonitis and erosions were documented as present (1) or absent (0).

PDUS was used for grading of synovitis and tenosynovitis/paratenonitis on the dorsal and palmar scan for each joint. PDUS of MTP joints was performed only on dorsal scan. Synovitis and tenosynovitis/paratenonitis on PDUS were scored on a semi-quantitative scale (grade 0-3) [32,33].

The scoring range was 0–27 for GSUS synovitis, 0–7 for GSUS tenosynovitis/paratenonitis, 0–39 for PDUS synovitis, and 0–21 for PDUS tenosynovitis/paratenonitis. US7-score was calculated as the sum of the synovitis score and tenosynovitis/paratenonitis score on GSUS and of the synovitis and tenosynovitis scores on PDUS. The sonographic examination of each patient took approximately 10-20 minutes, including documentation. US remission was defined as an absence of joints with PD signal, i.e. total PDUS score=0 [25].

Statistical analysis
The data was analyzed with the Statistical Package for the Social Sciences (SPSS), Version 24 [34]. Descriptive statistics included mean values ± standard deviation (SD) for continuously measured and normally distributed variables, and frequencies and percentages for dichotomous variables. The continuous demographic (age and disease duration), clinical (DAS28, SDAI, CDAI, CRP, HAQ, VAS) and sonographic (scores for GS synovitis, PD synovitis, GS tenosynovitis, PD tenosynovitis, erosion score (ErS), GSUS score, PDUS score, US7 score) variables at baseline were checked for normality with the Kolmogorov-Smirnov test which showed that in both the sDMARDs and bDMARDs group the assumption of normality was in place, (p>0.05). The baseline demographic, clinical and sonographic parameters in the treatment groups (sDMARDs and bDMARDs) were compared through an independent samples t-test. The proportions of baseline dichotomous data (gender, ACPA positive and IgM-RF positive) and the observed clinical and sonographic remission in the course of the treatment between the two groups were examined through the chi-square test. Statistical significance was considered at Type I error rate alpha ≤0.5.

Results

Characteristics of patients
One hundred and forty-one RA patients (79.0% women) of mean±SD age of 58.90±11.04 years and mean±SD disease duration of 87.62±97 months were enrolled. At inclusion, 90 patients (64.0%) were IgM-RF positive and 120 patients (81.0%) were ACPA positive. Seventy-eight patients (55.3%) were treated with sDMARDs and 63 (44.7%) with bDMARDs. In the sDMARDs group 69 patients (88.5%) were treated with conventional sDMARDs

| Table I. Patients’ demographic and clinical data at baseline |
|-----------------|-----------------|--------------------|-----------------|-----------------|
| **Variables**   | **Total** (N = 141) | **GROUP** | **GROUP** | **GROUP** |
| Age             | 58.90±11.04     | 60.47±11.37 | 59.20±10.68 | 0.500 |
| Gender          |                | Female         | 111(79)     | 65(83)        | 46(73)      | 0.137 |
|                |                | Male           | 30(21)      | 13(17)        | 17(27)      | |
| Disease duration|                | Months         | 87.62±97    | 73.5±101      | 105.20±89.26 | 0.053 |
|                |                | Newly diagnosed| 23(16)      | 22(28.2)      | 1(1.6)      | 0.0001 |
| ACPA positive   | 120(81)         | 59(75.6)       | 61(96.8)    | 0.0001 |
| IgM-RF positive | 90(64)          | 47(60)         | 43(68.3)    | 0.30 |
| DAS28           | 5.43±0.92       | 5.37±0.90      | 5.49±0.93   | 0.455 |
| SDAI            | 33.80±11.97     | 32.90±11.58    | 34.71±12.37 | 0.372 |
| CDAI            | 31.02±11.35     | 30.18±11.26    | 31.87±11.44 | 0.381 |
| CRP (mg/l)      | 27.47±26.50     | 27.23±19.62    | 28.32±33.50 | 0.811 |
| HAQ             | 1.54±0.63       | 1.49±0.66      | 1.72±0.60   | 0.035 |
| VAS (0-100)     | 74.18±12.75     | 72.95±11.96    | 75.40±13.53 | 0.257 |

The results are expressed as number (%) or mean±SD; N- number of patients; DAS28 – Disease Activity Score for 28 joints; SDAI – Simplified Disease Activity Index; CDAI – Clinical Disease Activity Index; CRP – C-reactive protein; IgM-RF – IgM-Rheumatoid factor; ACPA – anti-citrullinated protein antibodies; HAQ – Health Assessment Questionnaire; VAS -visual-analogue scale.
Musculoskeletal ultrasound as a biomarker of remission

csDMARDs) and 9 patients (11.50%) with targeted sDMARDs. In the bDMARDs group 47 patients (75%) were on combination therapy – csDMARDs and bDMARDs – and 16 patients (25%) were on bDMARDs monotherapy.

The two treatment groups did not differ significantly in the clinical indices for disease activity, CRP level and VAS pain level (table I).

The difference in the baseline US scores of the two treatment groups was not statistically significant, except for the erosion score, which was significantly higher in the bDMARDs group, p=0.002 (table II).

Clinical and sonographic remission after one year

The clinical and sonographic remission rates after 12-month treatment are summarized in table III. The highest rate of remission was observed in relation to DAS28. At month 12 none of the patients had achieved Gray Scale score of 0; hence, the results in table III summarize US remission according to PDUS (PDUS = 0).
Triangulation of the results of the clinical and PDUS remission is illustrated in figure 1. DAS28 remission with PD remission was present in 8 (23%) of the sDMARDs patients and in 9 (29%) of those in the bDMARDs group. Remission according to the rest of the clinical indices, SDAI, CDAI and Boolean remission, showed 100% overlap with PDUS remission in both patients’ groups.

In the sDMARDs group, PD remission was present in 8 (23%) patients in DAS28 remission and in all patients in SDAI, CDAI and Boolean remission. Synovial PD signal (PDUS score≥1) was detected in 26 (77%) of patients in DAS28 remission. In the bDMARDs group, PD remission (PDUS score=0) was present in 9 (29%) of patients in DAS28 remission, and in all patients in SDAI, CDAI and Boolean remission. Synovial PD signal (PDUS score≥1) was detected in 22 (71%) of patients in DAS28 remission.

Altogether, 65 RA patients (46%) achieved DAS28 remission and PDUS remission was present in 17 (26%) of these patients (fig 2).

Discussion

The achievement of true remission became a more realistic goal after the introduction of biologic treatment and “treat-to-target” strategy [35,36]. Evidence exists that all patients in clinical remission, irrespective of the used definition, may experience progression of the radiographic damage [37,38]. Nevertheless, research shows that stricter definitions are associated with a reduced likelihood of structural progression [37]. US examination as a sensitive imaging technique for the detection of synovitis may be needed to determine imaging remission [39-41]. This is important as US-detected synovitis in clinical remission is a predictor for a relapse and loss of remission [9,10,42].

A biomarker is an objectively measured indicator of the status of a biologic process or a disease. It defines various aspects of pathogenesis, disease activity, therapy response or a disease outcome [43]. The association of PDUS with histological findings supports the current opinion that PDUS is a biomarker of treatment response and reflects both clinical and histological markers of disease activity in patients with RA [44,45].

The aim of our study was to assess the role of the US7 score as a biomarker of remission and to compare the rates of clinical and imaging remission in a cohort of patients with RA receiving different types of treatment. Previous studies have shown that more patients achieve DAS28 remission as compared to CDAI, SDAI and ACR/EULAR remission [46,47] but at the same time more patients in DAS28 remission have persistent PD positive synovitis in comparison to patients in SDAI, CDAI or ACR/EULAR remission [39,46,48,49]. The results of our study are in agreement with the results of these studies. We decided to define imaging remission only on the basis of the PDUS score, ignoring GS changes because their significance in later RA remains uncertain [50]. We found that the rate of US remission at month 12 was higher for the bDMARDs group as compared to the sDMARDs group although the difference did not reach the significance level. Other authors have also found that the rate of imaging remission does not depend on the type of treatment (conventional or biologic) [51].

At month twelve, all patients had persistent synovial hypertrophy on GSUS (GSUS score≥1) and 48 patients (74%) patients in DAS28 remission had a persistent PD signal. All patients in CDAI, SDAI and Boolean remission had a negative PD signal (PDUS score=0). An important conclusion from our study is that there is an agreement between US remission and SDAI, CDAI and Boolean remission and a discordance between US and DAS28 remission both in patients on sDMARDs and on bDMARDs. Our opinion is that the SDAI, CDAI and Boolean definitions of remission are stricter than the DAS28 definition.

The problem of discordance between clinical and US remission was largely studied in the last years. Balsa et al have demonstrated that in relation to imaging remission there were no differences between DAS28 and ACR criteria, but SDAI better correlated with US remission [25]. Differences between DAS28 and SDAI were also demonstrated by Naredo et al [48]. Peluso et al showed a high proportion of patients with persistent synovitis using DAS criteria compared to the ACR criteria [9], while in a recent study Olmez et al demonstrated that CDAI was superior to other indices to assess remission [49]. Contrarily, Brahe et al [52] found that the US remission rates were only slightly lower and not statistically significant when using DAS28 over the other clinical criteria (SDAI, CDAI and ACR/EULAR). The authors also demonstrated that 1/3 of GS synovial hypertrophy was detected in the feet. This finding may explain the lack of correlation between DAS28 remission and US remission [52].

The key strength of our study is that it was conducted in a real-life setting with a large cohort of RA patients, who were followed for a period of one year at five visits. The rate of achievement of clinical and imaging remission was compared separately for patients treated with sDMARDs and with bDMARDs. From our study, we draw 3 important conclusions. First, we ascertain that there is discordance between clinical remission by DAS28 and US remission as we found that imaging
synovitis was present in patients with DAS28 remission. Second, we conclude that there is a higher rate of agreement between sonographic remission and clinical remission by the CDAI, SDAI and ACR/EULAR Boolean indices. Third, absence of GS imaging synovitis was not achieved within 12 months of therapy irrespective of the type of treatment.

There are also some limitations that need to be acknowledged. First, inter- and intra-observer agreement for the sonographic examination was not tested. The second and most important limitation refers to the lack of a gold standard for true remission against which the US method to be compared and evaluated as a biomarker of remission. The third limitation is the small number of patients fulfilling the stricter criteria for clinical remission (SDAI, CDAI, ACR/EULAR) which may have affected the precision of our estimates.

Conclusions

Clinical remission by DAS28 does not overlap imaging remission by MSUS. There is a persistence of imaging synovitis in RA patients in DAS28 clinical remission irrespective of the type of treatment. US may be a useful tool for the assessment of imaging remission and subclinical synovitis in patients in clinical remission.

Conflict of interest: none

References


46. Sakellariou G, Sciré CA, Verstappen SM, Montecucco C, Caporali R. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies pa-
460 Tanya Sapundzhieva et al

Musculoskeletal ultrasound as a biomarker of remission